Barclays analyst Balaji Prasad raised the firm’s price target on Viatris (VTRS) to $12 from $11 and keeps an Underweight rating on the shares. The post-earnings rally reflects capital allocation and an improving 2025 outlook, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTRS:
- Viatris Inc. Reports Strong Q3 2024 Performance
- Early notable gainers among liquid option names on November 7th
- VTRS Earnings this Week: How Will it Perform?
- Lexicon signs licensing agreement with Viatris for sotagliflozin
- Lexicon receives $25M upfront from Viatris for exclusive sotagliflozin license